Specialty drug prices and utilization after loss of U.S. patent exclusivity, 2001-2007
---- Acknowledgements -----
The efforts of Conti were funded by a K07 CA138906 award from the National Cancer Institute to the University of Chicago. Berndt's efforts were not sponsored. The funding source had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; and preparation, review, or approval of the manuscript for publication. The statements, findings, conclusions, views, and opinions contained and expressed in this article are those of the authors and are based in part on National Sales Perspectives™ data obtained by the National Bureau of Economic Research (NBER) under license from IMS Health, and are not necessarily those of IMS Health, its affiliates or subsidiaries, or the institutions with whom the authors are affiliated. We thank Ryan Conrad, David Cutler, Judy Hellerstein, Christopher Stromberg, Marta Wosinska and participants at the October 18-19, 2013 NBER/Conference on Research in Income and Wealth, "Measuring and Modeling Health Care Costs" in Washington, DC, and at the June 22-24, 2014 ASHEcon meetings in Los Angeles, for helpful comments. The views expressed herein are those of the authors and do not necessarily reflect the views of the National Bureau of Economic Research.